Biotech firm Jade Biosciences Inc. has completed its merger with Aerovate Therapeutics Inc. (Nasdaq:AVTE), in a move that will put the former on the Nasdaq.
Jade’s Vancouver-based CEO, Tom Frohlich, previously helped shepherd B.C.-based Chinook Therapeutics to a US$3.2-billion exit.
Monday’s announcement said the new company will operate under the Jade Biosciences Inc. banner and begin trading on the Nasdaq April 29 under the JBIO ticker symbol.
